Tylenol Autism Lawsuit in Alabama

Yes — the litigation is still active on two fronts. First, the federal appeal: the Second Circuit Court of Appeals heard oral arguments on November 17, 2025, reviewing whether Judge Denise Cote's August 2024 dismissal of MDL-3043 was legally correct. Two of three appellate judges openly questioned the dismissal during oral argument — a significant signal that a reversal is possible. A Second Circuit ruling is expected in 2026. Second, state courts: California and Illinois are actively handling acetaminophen-autism cases under the Frye admissibility standard, which is different from and more favorable than the federal Daubert standard that closed the MDL. Families who qualify should consult an attorney now to evaluate their options in both the federal appeal and state court forums.

The Second Circuit appeal challenges Judge Denise Cote's August 2024 Daubert ruling in MDL-3043. Judge Cote excluded all of the plaintiffs' general causation expert witnesses — the scientists retained to testify that prenatal acetaminophen can cause ASD and ADHD — finding their methodologies insufficiently reliable under federal evidentiary standards. Without those experts, plaintiffs could not prove causation, and the MDL was dismissed. The plaintiffs appealed, arguing that Judge Cote set the Daubert bar too high and improperly substituted her own scientific judgment for that of qualified experts. During oral arguments on November 17, 2025, two of the three Second Circuit judges asked pointed questions suggesting they believed the lower court may have been too aggressive — including questions about whether the case-specific evidence for individual plaintiffs should have survived even if the MDL-wide expert ruling stood. A reversal could reinstate the entire MDL or remand for further Daubert proceedings.

Yes. The federal MDL dismissal does not prevent you from filing in state court. California (Alameda County) and Illinois (St. Clair, Madison, Cook counties) are the most active state venues. These states apply the Frye standard for expert admissibility — not the federal Daubert standard that closed the MDL. Under Frye, the relevant question is whether the scientific methodology used by plaintiffs' experts is generally accepted in the relevant scientific community. The 91-scientist consensus statement in Nature Reviews Endocrinology (2021) provides strong evidence that the prenatal-exposure-to-neurodevelopmental-risk methodology is broadly accepted. Whether you can file in state court depends on your state's statute of limitations, your child's diagnosis, and your exposure history. Consult an attorney as soon as possible to evaluate your state-specific options.

Yes. ADHD-only diagnoses are explicitly covered in the acetaminophen litigation. The case is formally titled 'In re Acetaminophen — ASD/ADHD Products Liability Litigation' for exactly this reason — ADHD is a named injury alongside autism. The JAMA Psychiatry 2020 cord blood study found a 2.86 times increased risk of ADHD in children with the highest prenatal acetaminophen concentrations. Economically, ADHD carries documented lifetime costs including a $1.27 million estimated lifetime earnings gap. If your child was diagnosed with ADHD by a licensed clinician, and you took acetaminophen during pregnancy — any brand, including generic — you may have a viable claim. Consult an attorney to evaluate your specific eligibility.

No. The brand of acetaminophen does not affect your eligibility. The failure-to-warn legal theory applies equally to every product containing acetaminophen as the active ingredient — Tylenol (Kenvue/J&J), Walmart's Equate brand, CVS Health brand, Well at Walgreens, Target's Up & Up brand, Kirkland Signature (Costco), Kroger brand, Rite Aid brand, and any other private-label or generic version. More than 14 major retailers were named as defendants in MDL-3043 specifically because their private-label acetaminophen products carry the same failure-to-warn allegations as the Tylenol brand. If you used any acetaminophen product during pregnancy, you have the same potential claim regardless of where you bought it.

Research suggests the second and third trimesters are the highest-risk exposure windows for neurodevelopmental effects, because these are the periods of most active brain organization, synaptogenesis, and dopaminergic system development. However, prolonged or high-dose use during any trimester may support a claim. Some studies have found associations with first-trimester exposure as well, particularly for ADHD. The key factors plaintiffs' attorneys evaluate are (1) whether use occurred during the pregnancy at all, (2) the duration and frequency of use, and (3) whether the child's diagnosis is consistent with the type of neurodevelopmental impact associated with prenatal APAP exposure. Even occasional use during a high-risk trimester may be relevant. Consult an attorney to evaluate your specific exposure history.

The defendants named in MDL-3043 and related state court proceedings include Kenvue Inc. (formerly the consumer health division of Johnson & Johnson, which makes Tylenol), as well as over a dozen major retailers who sold private-label acetaminophen: Walmart, CVS, Walgreens, Rite Aid, Costco, Meijer, Target, Kroger, Albertsons, Dollar General, Family Dollar, Publix, H-E-B, and Amazon. These retailers are named because they manufactured and sold store-brand acetaminophen products without adequate warnings about the prenatal neurodevelopmental risk. If you purchased any of these store brands during pregnancy, you have a claim against the retailer who sold it, not just the brand manufacturer.

No Tylenol autism settlements have been finalized as of February 2026. The litigation is still in the appellate and state court phase. If and when the litigation resolves — either through a Second Circuit reversal reinstating the federal MDL, or through state court proceedings reaching verdict or settlement — projected values based on comparable neurodevelopmental mass torts and published cost-of-care research range from approximately $75,000 to $150,000 for ADHD-only claims, $150,000 to $400,000 for level 1 ASD or combined ASD+ADHD with moderate impact, $300,000 to $750,000 for level 2 ASD requiring substantial support, and higher for level 3 ASD with lifetime care documentation. These are projections, not guarantees, and the actual resolution value depends entirely on the outcome of the appellate and state court litigation.

The two categories of evidence needed are: (1) Proof of prenatal acetaminophen use — pharmacy prescription records, OTC purchase receipts, store loyalty card records showing acetaminophen purchases, medical records from prenatal visits documenting acetaminophen use or recommendation, and your own and your OB's recollection of what pain relievers were recommended. Tylenol was the nearly universally recommended pain reliever during pregnancy for decades, so physician recommendation is often the most reliable evidence. (2) Medical records establishing ASD or ADHD diagnosis — the official diagnostic evaluation report from a psychologist, developmental pediatrician, or psychiatrist; IEP or 504 records from school; treatment records for behavioral therapy, speech therapy, or ADHD medication; and any neuropsychological testing reports. Your attorney will help you gather pharmacy records and obtain complete medical records. You do not need to have saved any Tylenol packaging.

The scientific evidence is genuinely contested — which is why we address it directly. Plaintiff-favorable evidence includes: a 2018 American Journal of Epidemiology meta-analysis of 130,000+ mother-child pairs finding 20% higher ASD risk and 30% higher ADHD risk with prolonged prenatal acetaminophen use; the 2020 JAMA Psychiatry cord blood study finding 3.62x ASD risk and 2.86x ADHD risk in the highest-exposure group; and the 2021 Nature Reviews Endocrinology consensus statement signed by 91 scientists calling for precautionary guidance. Defense-favorable evidence includes: a 2024 Swedish JAMA study of 2.48 million children that found no causal link after adjusting for confounders, and a January 2026 Lancet review of 43 studies that also found no link. Judge Cote found the plaintiffs' experts did not adequately account for confounding — the concern that mothers who take more acetaminophen may have underlying conditions that independently increase autism risk. The Second Circuit must decide if that exclusion was legally correct. Legal viability does not require unanimous scientific consensus — it requires that qualified experts can reliably apply an accepted methodology to available evidence.

Yes — and it varies by state. Most states apply a 2 to 3-year statute of limitations for personal injury claims, running from the date of diagnosis or from the date you knew or reasonably should have known of the connection between prenatal acetaminophen use and your child's diagnosis (the discovery rule). Because widespread public awareness of the Tylenol-autism link only followed the 2021 consensus statement and 2022 MDL formation, discovery-rule arguments are strong for many 2025 and 2026 filers. Additionally, most states toll (pause) the statute of limitations for minors — the clock may not begin until your child turns 18. California, Illinois, New York, and most other states have minority tolling provisions. However, do not rely on tolling without professional evaluation — contact an attorney now to determine the specific deadline for your state and circumstances.

In September 2025, HHS Secretary RFK Jr. released a report identifying prenatal acetaminophen as a contributor to rising autism rates, and the Trump administration directed the FDA to evaluate updating acetaminophen warning labels. In October 2025, the Texas Attorney General filed suit against Johnson & Johnson and Kenvue for failure to warn about prenatal risks. These governmental actions are legally significant for plaintiffs in two ways: First, they support the Frye-standard general-acceptance argument in California and Illinois — when the U.S. Secretary of Health and Human Services concludes that prenatal acetaminophen is associated with autism, it is difficult for defendants to argue this theory lacks general acceptance in the scientific community. Second, they may accelerate FDA label change proceedings, which — if completed — would be powerful evidence of a known risk that defendants failed to warn about. These developments make preserving your claim now more important, not less.